TABLE 2.
Laboratory values: renal function, markers of hemostasis, thrombogenesis, fibrinolysis, and endothelial activation. Data are expressed as median (IQR)
| Patients with CKD (n = 120) | Healthy Controls (n = 30) | p | CKD stage 2 (n = 10) | CKD stage 3 (n = 20) | CKD stage 4 (n = 20) | CKD stage 5 (n = 20) | HD new starters (n = 10) | Established HD (n = 20) | Transplant (n = 20) | P | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Urea mmol/L | 15 (8,24) | 4.6 (4–5) | <.001 | 5 (5, 8) | 10 (7, 11) | 16 (14, 21) | 24 (18, 31) | 32 (30, 36) | 20 (16, 26) | 7 (6, 12) | <.001 |
| eGFR ml/min*/1.73 m2 | 18 (9,46) | 90 (80,90) | <.001 | 66 (64, 68) | 45 (35, 49) | 18 (18, 25) | 11 (9, 13) | 5 (4, 7) | 5 (4, 6) | 56 (40, 63) | <.001 |
| Hemoglobin g/L | 118 (105,131) | 138 (129, 142) | <.001 | 145 (136, 158) | 129 (123, 131) | 112 (103, 120) | 114 (105, 124) | 93 (86, 99) | 111 (104, 117) | 133 (121, 143) | <.001 |
| PCV | 0.38 (0.34, 0.42) | 0.42 (0.4, 0.44) | <.001 | 0.45 (0.43, 0.47) | 0.40 (0.38, 0.42) | 0.36 (0.34, 0.38) | 0.36 (0.33, 0.38) | 0.30 (0.28, 0.31) | 0.36 (0.34, 0.38) | 0.42 (0.38, 0.44) | <.001 |
| Platelets × 109/L | 233 (196, 275) | 263 (221, 286) | .044 | 248 (233, 289) | 240 (213, 269) | 246 (204, 290) | 200 (163, 269) | 293 (217, 369) | 207 (171, 236) | 234 (196, 262) | .018 |
| INR | 1.03 (0.99, 1.08) | 1.01 (0.95, 1.04) | N.S. | 0.98 (0.98, 1.05) | 1.0 (0.99, 1.06) | 1.02 (0.98, 1.04) | 1.03 (0.98, 1.08) | 1.10 (1.08, 1.12) | 1.05 (1.01, 1.19) | 1.03 (0.99, 1.07) | .002 |
| APTR | 1.04 (1.0, 1.11) | 1 (0.98, 1.08) | N.S. | 1.04 (0.98, 1.05) | 1.02 (1.0, 1.10) | 1.03 (0.96, 1.07) | 1.03 (0.96, 1.09) | 1.12 (1.02, 1.22) | 1.08 (1.03, 1.23) | 1.06 (0.98, 1.11) | N.S. |
| α‐2 antiplasmin μg/L | 2142 (452, 6148) | 2173 (993, 3640) | N.S. | 956 (255, 1795) | 2616 (471, 5734) | 2787 (576, 8000) | 3712 (594, 6738) | 1743 (800, 3035) | 702 (365, 19588) | 648 (291, 2690) | N.S. |
| PAI‐1 μg/L | 1.5 (1.1, 2.7) | 1.7 (1.0, 2.5) | N.S. | 1.4 (1.3, 2.2) | 1.5 (0.9, 2.5) | 1.4 (1.1, 2.4) | 1.4 (1.1, 1.5) | 0.8 (0.7, 1.0) | 2.0 (1.2, 3.4) | 3.1 (1.9, 4.6) | <.001 |
| TAT μg/L | 2.5 (1.8, 3.5) | 1.7 (1.0, 2.5) | .001 | 2.3 (1.8, 2.8) | 3.0 (2.3, 3.6) | 2.6 (2.2, 3.4) | 2.2 (1.8, 3.7) | 1.9 (1.5, 3.1) | 2.5 (1.5, 4.5) | 2.7 (2.0, 3.5) | N.S. |
| D‐dimer μg/L | 0.5 (0.3, 1.3) | 0. 2 (0.1, 0.3) | <.001 | 0.2 (0.1, 0.3) | 0.4 (0.3, 0.6) | 0.7 (0.4, 1.4) | 0.5 (0.3, 1.4) | 1.0 (0.6, 2.5) | 1.0 (0.4, 1.5) | 0.3 (0.2, 0.7) | .001 |
| ICAM‐1 μg/L | 281 (242, 325) | 222 (191, 248) | <.001 | 231 (182, 262) | 292 (258, 338) | 305 (268, 334) | 303 (262, 342) | 270 (219, 313) | 259 (240, 321) | 252 (208, 292) | .004 |
Abbreviations: APTR, activated partial thromboplastin ratio; eGFR, estimated glomerular filtration rate; ICAM‐1, intercellular adhesion molecule‐1; INR, international normalized ratio; N.S., non‐significant; PAI‐1, platelet activator inhibitor‐1; PCV, packed cell volume; TAT, thrombin antithrombin.